NASDAQ : GERN
Geron Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 0.9462 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 607.91M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 596.92M |
| Enterprise Value | 394.10M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 642.47M |
| Shares Outstanding | 642.47M |
| Shares Change (YoY) | +0.60% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 61.50% |
| Float | 556.31M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 82.22 |
| PS Ratio | 2.92 |
| Forward PS | 2.10 |
| PB Ratio | 2.73 |
| P/TBV Ratio | 2.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.92 |
| Quick Ratio | 5.04 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.17 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -28.28% |
| Return on Assets (ROA) | -4.11% |
| Return on Invested Capital (ROIC) | -6.11% |
| Return on Capital Employed (ROCE) | -7.86% |
| Weighted Average Cost of Capital (WACC) | 9.64% |
| Revenue Per Employee | $792,864 |
| Profits Per Employee | -$262,062 |
| Employee Count | 258 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 0.88 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -26.26% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 1.42 |
| Relative Strength Index (RSI) | 27.34 |
| Average Volume (20 Days) | 12,678,088 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 74.61M |
| Short Previous Month | 73.89M |
| Short % of Shares Out | 11.61% |
| Short % of Float | 13.41% |
| Short Ratio (days to cover) | 8.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 204.56M |
| Gross Profit | 119.67M |
| Operating Income | -35.28M |
| Pretax Income | -67.61M |
| Net Income | -67.61M |
| EBITDA | -34.80M |
| EBIT | -35.28M |
| Loss Per Share | -$0.10 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 300.85M |
| Total Debt | 122.14M |
| Net Cash | 202.83M |
| Net Cash Per Share | $0.32 |
| Equity (Book Value) | 218.61M |
| Book Value Per Share | 0.34 |
| Working Capital | 416.01M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -114.38M |
| Capital Expenditures | -386,000 |
| Depreciation & Amortization | 485,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -114.76M |
| FCF Per Share | -$0.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | 58.50% |
| Operating Margin | -17.25% |
| Pretax Margin | -33.05% |
| Profit Margin | -33.05% |
| EBITDA Margin | -17.01% |
| EBIT Margin | -17.25% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.60% |
| Shareholder Yield | -0.60% |
| Earnings Yield | -10.88% |
| FCF Yield | -19.23% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $3.63 |
| Price Target Difference | 290.16% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 41.87% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.17 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |